LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Kodu・Aktsiate loetelu・Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Suletud

SektorTervishoid

24.97 1.13

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

24.36

Max

25.5

Põhinäitajad
By Trading Economics
Sissetulek	258M 216M
Müük	280M 459M
P/E Sektori keskmine	66.083 77.671
Aktsiakasum	1.67
Kasumimarginaal	47.04
Töötajad	705
EBITDA	258M 228M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+54.54% upside

Turustatistika
By TradingEconomics
Turukapital	-751M 3B
Eelmine avamishind	23.84
Eelmine sulgemishind	24.97

Uudiste sentiment

By Acuity

30%

70%

104 / 374 Pingereas Healthcare

Apellis Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. dets 2025, 23:58 UTC

Omandamised, ülevõtmised, äriostud

Destination XL to Merge With Oaktree-Backed Fullbeauty Brands -- Update

11. dets 2025, 23:56 UTC

Tulu

Costco Logs Higher Sales, Eyes Expansion to Fuel Membership Growth -- Update

11. dets 2025, 23:03 UTC

Omandamised, ülevõtmised, äriostud

FTC Sues to Block Henkel's $725 Million Acquisition of Liquid Nails From PE Firm

11. dets 2025, 22:06 UTC

Omandamised, ülevõtmised, äriostud

Scentre to Sell $456 Million Westfield Chermside Mall Stake to Dexus-Managed Fund

11. dets 2025, 21:50 UTC

Tulu

Costco Same-Store Sales, Membership Fees Rose in 1Q

11. dets 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

11. dets 2025, 23:44 UTC

Market Talk

Nikkei May Rise After U.S. Stock Indexes Hit Record Highs -- Market Talk

11. dets 2025, 23:37 UTC

Market Talk

Gold Steady, Underpinned by Dollar's Weakness -- Market Talk

11. dets 2025, 23:31 UTC

Tulu

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11. dets 2025, 22:48 UTC

Omandamised, ülevõtmised, äriostud

FTC Sues to Block Henkel's $725M Acquisition of Liquid Nails From PE Firm

11. dets 2025, 22:35 UTC

Tulu

Costco Sold 4.5 Million Pies Ahead of Thanksgiving. Despite Earnings Beat, the Stock Fails to Gain Traction. -- Barrons.com

11. dets 2025, 22:30 UTC

Tulu

Broadcom Beats Earnings. The Stock Wavers After Customer Updates. -- Barrons.com

11. dets 2025, 22:09 UTC

Omandamised, ülevõtmised, äriostud

FTC Alleges Henkel Deal Would Combine Two Biggest Brands of Construction Adhesives Sold at Stores Like Home Depot, Leading to Higher Prices

11. dets 2025, 22:06 UTC

Omandamised, ülevõtmised, äriostud

FTC Sues to Block Henkel From Buying Loctite Competitor Liquid Nails

11. dets 2025, 22:05 UTC

Tulu

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11. dets 2025, 21:51 UTC

Omandamised, ülevõtmised, äriostud

Scentre to Sell $456M Westfield Chermside Mall Stake to Dexus-Managed Fund

11. dets 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

11. dets 2025, 21:39 UTC

Tulu

Broadcom Beats Earnings. The Stock Rises. -- Barrons.com

11. dets 2025, 21:39 UTC

Tulu

Broadcom Reports $18 Billion in Revenue as AI Chip Sales Climb -- WSJ

11. dets 2025, 21:38 UTC

Tulu

Costco Tops Earnings Estimates but Stock Fails to Gain Traction -- Barrons.com

11. dets 2025, 21:37 UTC

Tulu

These Stocks Moved the Most Today: Oracle, Nvidia, Broadcom, Planet Labs, Visa, Ciena, Gemini Space Station, and More -- Barrons.com

11. dets 2025, 21:37 UTC

Market Talk

Broadcom Sees AI Revenue Doubling -- Market Talk

11. dets 2025, 21:34 UTC

Omandamised, ülevõtmised, äriostud

Scentre Will Temporarily Invest A$50M in the New Dexus Fund

11. dets 2025, 21:29 UTC

Omandamised, ülevõtmised, äriostud

Dexus Aiming for Long-Term Holding of A$50M in Fund

11. dets 2025, 21:28 UTC

Market Talk

BLS Publishing Calendar Delays Now Pushing Economic Data Into February -- Market Talk

11. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

Dexus Expects to Introduce Additional Third-Party Equity in FY26

11. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

Dexus: Third Party Investors to Contribute Remainder

11. dets 2025, 21:27 UTC

Omandamised, ülevõtmised, äriostud

Dexus to Put Initial A$170M into New Dexus Strategic Investment Trust

11. dets 2025, 21:26 UTC

Omandamised, ülevõtmised, äriostud

Scentre: Dexus Wholesale Shopping Centre Fund Already Holds 25% Stake

11. dets 2025, 21:25 UTC

Omandamised, ülevõtmised, äriostud

Scentre: Purchase Price Represents Book Value, 5% Value Cap Rate

Võrdlus sarnastega

Hinnamuutus

Apellis Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

54.54% tõus

12 kuu keskmine prognoos

Keskmine 38.14 USD 54.54%

Kõrge 117.8 USD

Madal 18 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Apellis Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

15 ratings

Osta

Hoia

Müü

Põhineb 15 analüütiku instrumendi Apellis Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

104 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.